Sawusch M R, O'Brien T P, Dick J D, Gottsch J D
Wilmer Ophthalmological Institute, Baltimore, MD 21205.
Am J Ophthalmol. 1988 Sep 15;106(3):279-81. doi: 10.1016/0002-9394(88)90361-3.
We used an animal model of Pseudomonas keratitis to compare treatment by topical tobramycin with and without the presence of a commercially available collagen corneal shield. Pilot studies showed a significant, 30-fold increase in penetration of tobramycin into the anterior chamber in eyes with a collagen shield in place. Twenty albino rabbit eyes were inoculated with P. aeruginosa to produce stromal keratitis. After 12 hours of topical tobramycin dosing, eyes with a collagen corneal shield in place had a statistically significant (P less than .01) decrease in colony forming unit counts in comparison to treated eyes without a shield and control eyes.
我们使用铜绿假单胞菌性角膜炎动物模型，比较在有和没有市售胶原角膜屏障的情况下局部使用妥布霉素的治疗效果。初步研究表明，在佩戴胶原屏障的眼中，妥布霉素在前房中的渗透率显著增加了30倍。给20只白化兔眼接种铜绿假单胞菌以诱发基质性角膜炎。在局部使用妥布霉素给药12小时后，与未佩戴屏障的治疗眼和对照眼相比，佩戴胶原角膜屏障的眼在菌落形成单位计数上有统计学显著下降（P小于0.01）。
